Also Read: EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035.

All treatment arms in the PAVIA trial have reached at least three months post-dosing follow-up as of September 1, 2023.

Approximately 170 patients have received EYP-1901 with a minimum of three months of follow-up post-injection from the ongoing Phase 2 PAVIA and DAVIO 2 trials and the completed DAVIO 1 trial with no reported drug-related ocular severe adverse events (SAEs) and no reported drug-related systemic SAEs.

In the PAVIA clinical trial, there have been no reported drug-related ocular SAEs and drug-related systemic SAEs. There were two ocular SAEs deemed unrelated to EYP-1901 by investigators:

• Hemorrhagic posterior vitreous detachment (PVD) in a study eye eight weeks after dosing
• Macular edema leading to vision loss in the non-study fellow eye

The company remains on track to share topline results from the DAVIO 2 trial in December of this year and the PAVIA trial in the second quarter of 2024.

Price Action: EYPT shares are up 10.60% at $11.09 on the last check Monday.